Structural basis of valmerins as dual inhibitors of GSK3β/CDK5

被引:30
|
作者
Li, Xiaolong [1 ]
Wang, Xiaowei [2 ]
Tian, Zibin [2 ]
Zhao, Houling [1 ]
Liang, Da [1 ]
Li, Weisong [1 ]
Qiu, Yujin [1 ]
Lu, Shaoyong [3 ]
机构
[1] Weifang Med Univ, Affiliated Hosp, Depatment Spinal Surg, Weifang 261000, Peoples R China
[2] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Gastroenterol, Qingdao 266003, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Med Bioinformat Ctr, Shanghai 200025, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
GSK3; beta/CDK5; MD simulation; Molecular docking; MM-PBSA; PCA; MOLECULAR-DYNAMICS SIMULATION; CANCER-THERAPY; KINASE; MECHANISM; BINDING; RESISTANCE; MUTATION; MUTANTS;
D O I
10.1007/s00894-014-2407-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development of multi-target drugs is becoming increasingly attractive in the repertoire of protein kinase inhibitors discovery. In this study, we carried out molecular docking, molecular dynamics simulations, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations, principal component analysis (PCA), and dynamical cross-correlation matrices (DCCM) to dissect the molecular mechanism for the valmerin-19 acting as a dual inhibitor for glycogen synthase kinase 3 beta (GSK3 beta) and cyclin-dependent kinase 5 (CDK5). Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3 beta/CDK5 were calculated to be -12.60 +/- 2.28 kcal mol(-1) and -11.85 +/- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3 beta/CDK5. The analyses of PCA and DCCM results unraveled that binding of the valmerin-19 reduced the conformational dynamics of GSK3 beta/CDK5 and the valmerin-19 bound to GSK3 beta/CDK5 might occur mostly through a conformational selection mechanism. This study may be helpful for the future design of novel and potent dual GSK3 beta/CDK5 inhibitors.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [41] Design and synthesis of pyridones as CDK5 inhibitors.
    Kaller, MR
    Zhong, W
    Nguyen, TT
    Rzasa, RM
    Wang, HL
    Norman, MH
    Xiong, XL
    Powers, D
    Wang, WY
    Henley, C
    Magal, E
    Zhang, JD
    Osslund, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U132 - U132
  • [42] GSK3 inhibitors: development and therapeutic potential
    Philip Cohen
    Michel Goedert
    Nature Reviews Drug Discovery, 2004, 3 : 479 - 487
  • [43] GSK3 inhibitors: Development and therapeutic potential
    Cohen, P
    Goedert, M
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (06) : 479 - 487
  • [44] Novel Tricyclic Compounds as GSK3 Inhibitors
    Li, Yinlong
    Liang, Steven H.
    ACS MEDICINAL CHEMISTRY LETTERS, 2025,
  • [45] Dissociation of tau toxicity and phosphorylation: role of GSK-3β, MARK and Cdk5 in a Drosophila model
    Chatterjee, Shreyasi
    Sang, Tzu-Kang
    Lawless, George M.
    Jackson, George R.
    HUMAN MOLECULAR GENETICS, 2009, 18 (01) : 164 - 177
  • [46] Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5
    Amitabha Sengupta
    Qiongli Wu
    Inge Grundke-Iqbal
    Khalid Iqbal
    Toolsee J. Singh
    Molecular and Cellular Biochemistry, 1997, 167 : 99 - 105
  • [47] Cytoskeletal alterations induced apoptosis in cerebellar granule cells by Cdk5/GSK-3β activation
    Jorda, E. G.
    Canudas, A.
    Alvira, D.
    Jimenez, A.
    Folch, J.
    Mbau, V. R.
    Sureda, F. X.
    Verdaguer, E.
    Pallas, M.
    Camins, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 121 - 121
  • [48] Prenatal bisphenol A exposure contributes to Tau pathology: Potential roles of CDK5/GSK3β/PP2A axis in BPA-induced neurotoxicity
    Xue, Jing
    Zhang, Li
    Xie, Xuexue
    Gao, Yue
    Jiang, Lei
    Wang, Jun
    Wang, Yu
    Gao, Rong
    Yu, Jing
    Xiao, Hang
    TOXICOLOGY, 2020, 438
  • [49] Involvement of D1 dopamine receptor signaling in hyper-phosphorylation of the microtubule associated protein tau: A pivotal role for CDK5 and GSK3
    Le Bel, M.
    Cyr, M.
    MOVEMENT DISORDERS, 2008, 23 (01) : S86 - S87
  • [50] Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inductors of Structural Neuronal Plasticity
    Llorach-Pares, Laura
    Rodriguez-Urgelles, Ened
    Nonell-Canals, Alfons
    Alberch, Jordi
    Avila, Conxita
    Sanchez-Martinez, Melchor
    Giralt, Albert
    BIOMOLECULES, 2020, 10 (04)